Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

You’ve decided to start a GLP-1 medication. The next question — the one that determines a lot about your experience and your results — is which one. Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) are the two most-prescribed GLP-1-class medications in the United States. They are often discussed as if they are interchangeable. They are not.

This article is a clinical comparison of the two medications: what each one is, how they differ mechanically, what the clinical trial data actually shows, what the side effect profile looks like in real practice, and how a physician decides which medication fits which patient.

The short answer

Tirzepatide produces greater average weight loss and stronger metabolic effects in clinical trials. Semaglutide has a longer real-world track record, broader insurance coverage, and a slightly more familiar side effect profile. Neither is universally “better” — the right choice depends on your specific clinical picture, your goals, your tolerance for side effects, and what you are able to access through your insurance or out of pocket. A physician should be helping you make this decision, not a checkout flow. That principle is at the core of how we structure our medical weight loss service.

What semaglutide is

Semaglutide is a 31-amino-acid peptide modified for stability so it can be injected once weekly. It is a GLP-1 receptor agonist — meaning it mimics the action of glucagon-like peptide-1, a hormone your gut naturally produces after meals. GLP-1 has several effects: it stimulates insulin release in response to glucose, slows gastric emptying so you feel full longer, and acts on appetite centers in the brain to reduce hunger signaling.

Semaglutide is FDA-approved under two brand names. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management in patients meeting specific BMI criteria. The molecule is the same; the dosing schedules and approved indications differ.

Semaglutide has been on the market since 2017 and has accumulated substantial real-world data alongside its clinical trial evidence. Most physicians prescribing GLP-1 therapy have years of experience managing it. For the deeper clinical reference, see the semaglutide library entry; for how it’s prescribed in our clinic, see the semaglutide treatment page.

What tirzepatide is

Tirzepatide is also a once-weekly injectable peptide, but it is structurally different from semaglutide in an important way: it is a dual agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in metabolic regulation, and the combined effect of activating both pathways produces stronger results in clinical trials than activating GLP-1 alone.

Tirzepatide is FDA-approved under two brand names. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. As with semaglutide, the molecule is the same across both indications.

Tirzepatide was approved in 2022, so it has less long-term real-world data than semaglutide, but the clinical trial evidence is robust and the practitioner experience is rapidly accumulating. The tirzepatide library entry covers the dual-agonist mechanism in more detail, and our tirzepatide treatment page describes how we prescribe and monitor it.

Efficacy: what the clinical trials show

The clinical trials are not perfectly comparable — they used different patient populations, different doses, and different endpoints — but the broad pattern is consistent. In the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide, the average weight loss results were as follows:

• Semaglutide (2.4 mg weekly, the weight management dose): approximately 15 percent average body weight loss at 68 weeks in patients without diabetes.
• Tirzepatide (15 mg weekly, the highest dose): approximately 21 percent average body weight loss at 72 weeks in patients without diabetes.

A head-to-head trial called SURMOUNT-5 compared the two medications directly in 2024 and confirmed tirzepatide produced greater weight loss than semaglutide in the same patient population, with a difference of approximately 6 percentage points favoring tirzepatide.

The implication for an individual patient: tirzepatide tends to produce more weight loss on average, but average is not individual. Some patients respond better to semaglutide than they do to tirzepatide, and we have seen this in our clinic. The mechanism matters, but so does individual metabolic response, which cannot be predicted in advance with current science. This is one of the reasons follow-up at 30, 60, and 90 days matters — to assess actual response and adjust if needed. Our Metabolic Reset program is structured around exactly this kind of ongoing assessment.

Side effects: what to expect

The side effect profiles of semaglutide and tirzepatide are broadly similar because both act on GLP-1 pathways. The most common side effects are gastrointestinal: nausea, decreased appetite, diarrhea or constipation, and occasional vomiting. These are most pronounced during dose escalation and typically diminish as the body adapts.

In our clinical experience, tirzepatide tends to produce slightly less GI distress per unit of weight loss than semaglutide — possibly because the GIP component modulates some of the GI effects. But this varies significantly by patient. Some patients tolerate semaglutide easily and find tirzepatide difficult. Others have the opposite experience.

More serious but rare adverse events for both medications include pancreatitis, gallbladder issues, and contraindications related to medullary thyroid carcinoma. Both medications carry a boxed warning related to thyroid C-cell tumors based on animal studies — though the human relevance remains uncertain, the warning means these medications should not be used in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Proper titration matters enormously. Patients who start at too high a dose or escalate too quickly experience disproportionate side effects without proportional benefit. A physician-managed titration protocol — adjusting based on response and tolerance rather than a fixed calendar — is the difference between a tolerable course and an unpleasant one.

Cost and access

Cost and access are real factors in this decision, and we are going to be direct about them.

Brand-name semaglutide (Ozempic, Wegovy) and brand-name tirzepatide (Mounjaro, Zepbound) are expensive without insurance coverage. Retail prices are typically $1,000 or more per month. Insurance coverage varies widely — some plans cover these medications for diabetes but not for weight management, some require prior authorization, and some do not cover them at all.

Compounded versions of both medications have been available through 503A compounding pharmacies during periods when the brand-name products were on the FDA shortage list. The FDA has been updating shortage status periodically, and the availability of compounded semaglutide and tirzepatide has changed over time. As of this writing, the regulatory landscape is fluid. A clinic that can clearly explain the current legal status of any compounded product they are prescribing — and where it is sourced from — is operating appropriately. A clinic that cannot is not. Our clinical standards page describes our sourcing approach in detail.

For patients without insurance coverage of brand-name products, compounded options have been the primary access route. The cost is meaningfully lower, but the quality depends entirely on the compounding pharmacy. Sourcing matters.

How a physician decides between them

When a patient enters our Metabolic Reset program, the choice between semaglutide and tirzepatide is made based on several factors:

Metabolic profile. Patients with significant insulin resistance, metabolic syndrome features, or substantial weight to lose may benefit from the stronger effect of tirzepatide. Patients with more modest metabolic disruption may respond well to semaglutide and not need the additional effect.

Side effect history. Patients who have previously tried one of these medications and tolerated it well usually do well restarting it. Patients who tolerated one poorly may do better on the other due to differences in GI effects.

Goals and timeline. Patients seeking a specific outcome by a specific date may benefit from the stronger weight loss profile of tirzepatide. Patients with a longer time horizon and a preference for the more established option may prefer semaglutide.

Access and cost. If insurance covers one and not the other, that often determines the practical choice. If both are out of pocket, cost differences and current shortage status factor in.

Medical history. Both medications have similar contraindications, but individual medical history may favor one over the other in specific cases.

The decision is rarely binary. We have patients who started on semaglutide, transitioned to tirzepatide for additional effect, and patients who tried tirzepatide, experienced significant side effects, and transitioned to semaglutide for better tolerability. The right answer for any individual patient is the one that produces the best results with the best tolerance over time, not the one with the highest average weight loss in a clinical trial.

What is not in the comparison

It is worth saying what is not part of this comparison. Neither semaglutide nor tirzepatide is a substitute for the foundational pieces of metabolic health: sleep, training, nutrition quality, stress management. They are powerful tools that amplify the work, not replacements for it. Patients who use either medication while continuing the metabolic habits that contributed to their starting condition often regain weight when the medication is stopped or paused.

Neither medication is a permanent solution by default. Both can be used long-term in appropriate patients, but the decision to stay on therapy versus taper off should be based on metabolic markers, body composition, and goals — not on assumption or fear of regain. This is part of what ongoing physician monitoring is for.

And neither medication is the right answer for every patient who walks into a metabolic clinic. For some patients, the underlying problem is not metabolic in the way GLP-1 medications address. For others, lifestyle intervention alone is sufficient. A clinic willing to say “this is not the right tool for you” is doing the work properly. A clinic that prescribes GLP-1 to anyone who walks in is not.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas, located adjacent to the Texas Medical Center. Our medical weight loss service and Metabolic Reset program are built around physician-designed GLP-1 protocols with comprehensive metabolic biomarker tracking, monthly check-ins, and physician-managed titration. We prescribe both semaglutide and tirzepatide, selecting between them based on clinical picture rather than convenience. We source from vetted 503A and 503B compounding pharmacies and prescribe FDA-approved products where appropriate.